EyeSense AG
EyeSense AG (FiberSense) is a Germany-based medical device company developing a CE-marked Class IIb continuous glucose monitoring system using proprietary fiber optic biosensor technology for adults with diabetes in the European Union.
- Company typePrivate
- Founded2006
- HeadquartersGroßostheim, Germany
- Headcount1–10
- GTM typeB2C
- OfferingHardware or Manufacturing
What EyeSense AG does
EyeSense AG, operating commercially as FiberSense, is a Germany-based privately held medical device company founded in 2006 as a spin-off from CIBA Vision (Alcon, ex-Novartis Group) and headquartered in Großostheim with a stated 1–10 employee footprint. The company has spent approximately two decades developing optical sensor technology for medical applications, which it now packages into the FiberSense CGM (Continuous Glucose Monitoring) System — a CE-marked Class IIb medical device under EU Regulation 2017/745. The system uses a fiber optic biosensor placed on the upper arm or abdomen to measure glucose concentrations in interstitial fluid via light-based sensing, paired with a reusable electronic detector that wirelessly transmits data to the FiberSense companion mobile app, intended for home use by adults (18+) with diabetes in the EU.
The core product architecture is a three-component system: a single-use sensor with up to 28-day wear duration, a reusable detector designed to reduce electronic waste, and a mobile app for real-time glucose visualization. The company generates revenue through hardware sales of both the recurring disposable sensors and the reusable detector, though no public pricing is disclosed and current sales are routed through a website contact form rather than e-commerce, with the companion app described as 'coming soon' on the Apple App Store and Google Play. Distribution is direct-to-consumer and regional (Germany/Europe), with no disclosed pharmacy, DME distributor, or payor reimbursement contracts in the source material.
Commercial readiness signals include CE certification, an active investor relations page, a live careers portal (Personio), and a publicly referenced forward-looking initiative called 'Project Nuvia'. The company has one disclosed early-stage financing round of approximately $8.2 million in February 2006 led by BioMedPartners and EQT Life Sciences with Novartis Venture Fund participation, and no subsequent funding rounds or revenue figures appear in the input data, consistent with a pre-launch commercial posture.
EyeSense AG firmographics
Firmographics- Name
- EyeSense AG
- Legal name
- EyeSense AG
- Website
- https://eyesense.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- EyeSense AG (FiberSense) is a Germany-based medical device company developing a CE-marked Class IIb continuous glucose monitoring system using proprietary fiber optic biosensor technology for adults with diabetes in the European Union.
- Ownership category
- akta.pro rank
EyeSense AG industry classification
Industry- Product category
- Continuous Glucose Monitoring Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Continuous Glucose Monitoring (CGM) Systems (HLAHAHAA)
- akta.pro secondary industry
- Diabetes Care Device Accessories & Adhesives (Sensors/Pump Supplies) (HLAHAHAL)
Keywords
Where EyeSense AG is headquartered
LocationHeadquarters
- HQ city
- Großostheim
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
EyeSense AG business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales
Revenue model
- CGM Sensor Sales: Sale of disposable fiber optic glucose sensors designed for up to 28-day wear duration before replacement. Sensors are the recurring consumable component of the system.
- Reusable Detector Hardware: Sale of the reusable electronic detector unit that attaches to the sensor and transmits data to the mobile app. This is a one-time or periodic hardware purchase.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
EyeSense AG product offering
Product offeringCore offering
EyeSense AG develops and sells the FiberSense CGM System, a CE-certified Class IIb continuous glucose monitoring medical device that uses fiber optic biosensor technology to measure glucose concentrations in interstitial fluid under the skin. The system comprises a single-use sensor worn on the upper arm or abdomen for up to 28 days, a reusable detector that wirelessly transmits data, and the FiberSense companion mobile app, and is intended for home use by adults with diabetes in the European market.
Product overview
EyeSense AG offers a single unified product portfolio built around the FiberSense CGM System, which consists of three integrated components: a disposable fiver-optic biosensor (worn on the upper arm or abdomen for up to 28 days), a reusable electronic detector that captures and transmits sensor signals wirelessly, and the companion FiberSense mobile app that delivers real-time glucose values and trends to the user's smartphone. The system is a CE-marked Class IIb medical device under EU Regulation 2017/745, designed for home use by adults with diabetes. The reusable detector and disposable sensor architecture is designed to reduce single-use waste compared to conventional CGM systems.
Differentiator
Problem solved
Functional benefit
Brands
- FiberSense CGM System: CE-certified continuous glucose monitoring system using fiber optic biosensor technology for people with diabetes. The system includes a sensor (worn up to 28 days), reusable detector, and mobile app for real-time glucose tracking.
Products and services
- FiberSense CGM System
Quantifiable outcome
- Up to 28-day sensor wear duration before replacement
Companies that use EyeSense AG
Customer profileSegments1 record
Ideal customer profiles1 record
EyeSense AG technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
EyeSense AG partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CIBA Vision (Alcon)minorHistorical corporate relationship: EyeSense originated as a spin-off from CIBA Vision (Alcon), which was formerly part of the Novartis Group. This relationship established EyeSense's foundation in optical sensor technology for medical applications in 2006, but does not represent an active commercial partnership.
Scale indicators2 records
Recent moves4 records
Expansion highlights5 records
EyeSense AG competitors and assessment
Company assessmentBroad incumbents
- Roche Diabetes Care: Incumbent diabetes care franchise with Accu-Chek blood glucose meters and the newer Accu-Chek Smart CGM (developed with Senseonics). Comparable as a broad European incumbent operating across both BGM and CGM categories with established payor relationships.
- Ascensia Diabetes Care: Spun out of Bayer Diabetes Care, focused on CONTOUR blood glucose monitoring with EU distribution strength. Comparable as a diabetes monitoring incumbent with similar CE-marked device portfolio and direct-to-patient EU GTM motion.
- LifeScan: Maker of OneTouch blood glucose meters and a peer-to-peer diabetes monitoring brand for consumers. Comparable on the diabetes self-management use case and BGM/CGM consumable model, though primarily U.S.-anchored.
Direct peers
- Abbott Diabetes Care: Maker of FreeStyle Libre, the world's highest-volume CGM by installed base. Competes head-to-head with FiberSense on continuous interstitial glucose sensing for adults with diabetes, with factory-calibrated sensors and a CE-marked/FDA-cleared consumable business model.
- Medtronic Diabetes: Operates the Guardian CGM line integrated with MiniMed insulin pumps and automated insulin delivery systems. Directly comparable as a Class IIb CE-marked CGM device targeting adult insulin-requiring diabetes patients in Europe.
- Dexcom: Global leader in CGM systems (G6, G7) with dominant market share, integrated insulin pump partnerships, and broad pediatric/adult indications. Most directly comparable to FiberSense on product category (continuous glucose monitoring for diabetes), target customer (people with diabetes), and CE/FDA-cleared medical device status.
- Ypsomed: Swiss diabetes care company offering mylife Loop automated insulin delivery with CGM integration, plus insulin pump and pen consumables. Directly comparable as a mid-sized European diabetes device company with CE-marked products and EU-centric commercial focus.
Emerging players
- Afon Technology: UK-based developer of a wearable, needle-free continuous glucose sensor using novel sensor technology. Comparable as a small European emerging player attempting to commercialize a non-conventional continuous glucose monitoring architecture.
- Senseonics: Makes Eversense, an implantable long-duration CGM using a fluorescent sensor — a non-electrochemical optical sensing approach with a similar technological premise to FiberSense's optical biosensor. Comparable as a small-cap, novel-modality CGM challenger with CE and FDA approvals.
- Biolinq: Early-stage developer of a needle-free, intradermal biosensor patch for continuous metabolite monitoring. Comparable as a small, novel-modality emerging player in continuous biosensing pursuing wearable, minimally invasive glucose/multi-analyte monitoring.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
EyeSense AG social profiles
Digital presenceEyeSense AG compliance and trust
Trust signalCompliance1 record
EyeSense AG financial estimates
Financial estimateRevenue estimate
Valuation estimate
EyeSense AG leadership team
Management profileNumber of profiles
EyeSense AG funding detail
Funding detailFunding overview
Funding rounds1 record
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EyeSense AG M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EyeSense AG
What does EyeSense AG do?
EyeSense AG develops and sells the FiberSense CGM System, a CE-certified Class IIb continuous glucose monitoring medical device that uses fiber optic biosensor technology to measure glucose concentrations in interstitial fluid under the skin. The system comprises a single-use sensor worn on the upper arm or abdomen for up to 28 days, a reusable detector that wirelessly transmits data, and the FiberSense companion mobile app, and is intended for home use by adults with diabetes in the European market.
Is EyeSense AG a public or private company?
EyeSense AG is a private company. It is classified as venture growth investor backed and is currently operating.
When was EyeSense AG founded?
EyeSense AG was founded in 2006. It employs 1 to 10 people.
Where is EyeSense AG based?
EyeSense AG is headquartered in Großostheim, Germany, in the Europe region.
How does EyeSense AG make money?
Two revenue lines are on record. CGM Sensor Sales are the primary driver. The others are reusable Detector Hardware.
Who are EyeSense AG's main competitors?
Broad incumbents on record are Roche Diabetes Care, Ascensia Diabetes Care and LifeScan. Direct peers are Abbott Diabetes Care, Medtronic Diabetes, Dexcom and Ypsomed. Emerging players are Afon Technology, Senseonics and Biolinq.
Does EyeSense AG have an API?
No public API is recorded for EyeSense AG.
What industry is EyeSense AG in?
EyeSense AG's product category is Continuous Glucose Monitoring Medical Devices. Its primary akta.pro industry code is HLAHAHAA, Continuous Glucose Monitoring (CGM) Systems, with a secondary code of HLAHAHAL, Diabetes Care Device Accessories & Adhesives (Sensors/Pump Supplies). Its NAICS code is 334510 and its SIC code is 3845.